The biochemical and radiological responses to radionuclide therapy with ^177^Lu-PSMA-617 targeting prostate-specific membrane antigen (PSMA) make it a promising approach to the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) \[[@CR1]\]. However, PSMA-617 has been reported to have slower tumour accumulation and clearance kinetics than PSMA-11, and the latter is still therefore the preferred diagnostic agent when labelled with generator-produced ^68^Ga which has a short half-life (68 min) \[[@CR2]\]. A PSMA-targeting ^18^F-labelled PET tracer could be produced with higher activity in a cyclotron and the half-life (110 min) would allow both late imaging beyond 1 h after injection and shipping to satellite institutions. However, the structure of the currently most-used ^18^F-labelled PSMA tracer, ^18^F-DCFPyl, is different from that of PSMA-617, and like PSMA-11 it might be a suboptimal surrogate for stratifying patients according to their suitability for therapy with ^177^Lu-PSMA-617 \[[@CR3]\].

Based on the scaffold of PSMA-617, the novel compound ^18^F-PSMA-1007 was developed. As shown in the image (**a**, **d**), PSMA-1007 shares the Glu-urea-Lys motif targeting the catalytic domain of PSMA and the naphthalene-based linker region considered to cotarget the hydrophobic accessory pocket \[[@CR4]\], while in the radiolabel-bearing moiety glutamic acids were added to mimic the carboxylic acid groups of the DOTA chelator to retain the polar charge influencing clearance kinetics.

The image also shows a patient with mCRPC who was staged using ^18^F-PSMA-1007 (**b** PET 1 h after injection, maximum intensity projection) and treatment with ^177^Lu-PSMA-617 (**c** planar scan 24 h after injection, geometric mean). In analogy to the chemical structure, the uptake in tumour and normal organs is very similar with the two compounds.

Thus, ^18^F-PSMA-1007 and ^177^Lu-PSMA-617 seem to be a perfect theragnostic tandem. Due to the preferred physical characteristics of ^18^F for PET imaging and the possibility for large-scale production in a cyclotron, ^18^F-PSMA-1007 is also a promising alternative to ^68^Ga-PSMA-11 for diagnostic purposes. However, non-inferior diagnostic accuracy has still to be proven in a larger cohort.

^18^F-PSMA-1007 is the subject of a patent application (EP 15 002 800.9, DKFZ)
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Written informed consent for imaging with an experimental tracer and publication of the individual patient history was obtained.
